Avidity Biosciences (RNA) Competitors $29.13 -0.23 (-0.78%) Closing price 07/3/2025 02:28 PM EasternExtended Trading$29.13 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNA vs. GMAB, RDY, QGEN, VTRS, ASND, MRNA, BBIO, BPMC, VRNA, and ROIVShould you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Moderna (MRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Avidity Biosciences vs. Its Competitors Genmab A/S Dr. Reddy's Laboratories QIAGEN Viatris Ascendis Pharma A/S Moderna BridgeBio Pharma Blueprint Medicines Verona Pharma PLC American Depositary Share Roivant Sciences Avidity Biosciences (NASDAQ:RNA) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk. Does the media refer more to RNA or GMAB? In the previous week, Genmab A/S had 1 more articles in the media than Avidity Biosciences. MarketBeat recorded 2 mentions for Genmab A/S and 1 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.00 equaled Genmab A/S'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in RNA or GMAB? 7.1% of Genmab A/S shares are owned by institutional investors. 3.8% of Avidity Biosciences shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend RNA or GMAB? Avidity Biosciences presently has a consensus price target of $65.59, indicating a potential upside of 125.16%. Genmab A/S has a consensus price target of $37.60, indicating a potential upside of 84.22%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Avidity Biosciences is more favorable than Genmab A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 1 Strong Buy rating(s) 3.06Genmab A/S 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.67 Which has more volatility & risk, RNA or GMAB? Avidity Biosciences has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Is RNA or GMAB more profitable? Genmab A/S has a net margin of 35.11% compared to Avidity Biosciences' net margin of -4,136.00%. Genmab A/S's return on equity of 18.08% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Avidity Biosciences-4,136.00% -26.96% -24.57% Genmab A/S 35.11%18.08%14.52% Which has preferable valuation & earnings, RNA or GMAB? Genmab A/S has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvidity Biosciences$10.90M322.09-$322.30M-$3.00-9.71Genmab A/S$3.12B4.19$1.14B$1.7611.60 SummaryGenmab A/S beats Avidity Biosciences on 10 of the 15 factors compared between the two stocks. Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNA vs. The Competition Export to ExcelMetricAvidity BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.52B$2.89B$5.56B$9.04BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-9.7121.7127.6620.25Price / Sales322.09281.81415.41118.18Price / CashN/A42.7336.8958.07Price / Book2.447.518.035.67Net Income-$322.30M-$55.14M$3.18B$249.21M7 Day Performance0.34%4.61%2.93%3.27%1 Month Performance-18.15%4.72%3.75%5.55%1 Year Performance-25.31%5.92%35.20%21.08% Avidity Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAAvidity Biosciences1.8242 of 5 stars$29.13-0.8%$65.59+125.2%-21.7%$3.52B$10.90M-9.71190GMABGenmab A/S3.5819 of 5 stars$20.66+0.8%$37.60+82.0%-18.8%$13.15B$3.12B14.752,682RDYDr. Reddy's Laboratories2.71 of 5 stars$15.03-0.3%$16.95+12.8%-0.9%$12.58B$3.81B22.7727,811QGENQIAGEN4.0478 of 5 stars$48.07+0.6%$49.40+2.8%+22.5%$10.62B$1.98B120.525,765Dividend AnnouncementVTRSViatris2.6812 of 5 stars$8.93-0.9%$10.40+16.5%-10.9%$10.57B$14.74B3.6332,000ASNDAscendis Pharma A/S3.5057 of 5 stars$172.60+0.2%$220.67+27.8%+29.7%$10.53B$393.54M-27.481,017News CoverageAnalyst ForecastMRNAModerna4.3855 of 5 stars$27.59+1.6%$46.61+68.9%-73.7%$10.50B$3.24B0.005,800Options VolumeBBIOBridgeBio Pharma4.6902 of 5 stars$43.18-3.7%$58.85+36.3%+74.8%$8.52B$221.90M0.00400News CoverageInsider TradeAnalyst RevisionHigh Trading VolumeBPMCBlueprint Medicines1.5646 of 5 stars$128.18+0.1%$128.06-0.1%+17.6%$8.27B$508.82M-51.89640VRNAVerona Pharma PLC American Depositary Share2.625 of 5 stars$94.58+0.8%$101.10+6.9%+480.4%$7.99B$42.28M-47.2930Positive NewsAnalyst ForecastROIVRoivant Sciences1.5492 of 5 stars$11.27-1.1%$17.50+55.3%+3.5%$7.74B$29.05M-45.08860 Related Companies and Tools Related Companies Genmab A/S Competitors Dr. Reddy's Laboratories Competitors QIAGEN Competitors Viatris Competitors Ascendis Pharma A/S Competitors Moderna Competitors BridgeBio Pharma Competitors Blueprint Medicines Competitors Verona Pharma PLC American Depositary Share Competitors Roivant Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNA) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNA Stock Alerts